Affordable Access

Access to the full text

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

Authors
  • Sakai, Makoto
  • Sohda, Makoto
  • Saito, Hideyuki
  • Kuriyama, Kengo
  • Yoshida, Tomonori
  • Kumakura, Yuji
  • Hara, Keigo
  • Yokobori, Takehiko
  • Miyazaki, Tatsuya
  • Murata, Kazutoshi
  • Noda, Shin-ei
  • Nakano, Takashi
  • Kuwano, Hiroyuki
  • Shirabe, Ken
Type
Published Article
Journal
Cancer Chemotherapy and Pharmacology
Publisher
Springer-Verlag
Publication Date
Apr 09, 2019
Volume
83
Issue
6
Pages
1121–1126
Identifiers
DOI: 10.1007/s00280-019-03835-0
Source
Springer Nature
Keywords
License
Yellow

Abstract

BackgroundTo evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for cervical esophageal cancer (CEC), we performed a retrospective analysis of CEC patients treated by DCF-RT at a single institution.MethodsWe conducted a single-center retrospective study. Twenty-one patients with CEC who underwent DCF-RT between 1999 and 2017 at our institute were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m2 on day 1, intravenous CDDP at 60 mg/m2 on day 1, and intravenous 5-FU at 600 mg/m2 on days 1–4, repeated every 4 weeks for two cycles. Among the 21 patients, six were irradiated using three-dimensional conformal RT (3D- conformal RT) and 15 were treated using intensity-modulated RT (IMRT) consisting of 60 Gy in 30 fractions.ResultsThe median follow-up period was 49.6 months (range 4.6–97.6). The overall complete response (CR) and local CR rates were 61.9% and 81.0% for all patients, and 76.9% and 84.6% for patients without hypopharyngeal and/or thoracic esophageal invasion, respectively. The 3-year overall survival (OS), progression-free survival (PFS), and local failure-free survival (LFFS) rates were 79.6, 52.4, and 74.7%, respectively. Grade 3–4 leucopenia developed in 12 patients (70.6%), neutropenia developed in 13 patients (81.2%), and mucositis developed in 2 patients (9.5%). There were no treatment-related deaths.ConclusionsThe 3-year OS and LFFS of patients who underwent DCF-RT were higher than those in the previous studies. Although the high rate of myelosuppression requires careful management, DCF-RT is a safe and effective modality for CEC.

Report this publication

Statistics

Seen <100 times